Browse News
Filter News
Found 808,988 articles
-
The Swiss drugmaker raised its full-year guidance Tuesday projecting net sales to grow in the high-single to low double-digit range while reporting better-than-expected first-quarter results.
-
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
-
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.
-
Bouncing back from a previous rejection, ImmunityBio on Monday secured the FDA’s green light for its IL-15 superagonist Anktiva for non-muscle invasive bladder cancer.
-
The U.S. Supreme Court on Monday indicated that it will not hear Vanda Pharmaceuticals’ petition in its patent case against Teva Pharmaceuticals regarding the former’s sleep-wake disorder drug Hetlioz.
-
The regulator on Monday slapped Abeona Therapeutics with a Complete Response Letter for its investigational cell therapy pz-cel due to chemistry, manufacturing and controls issues.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
4/23/2024
Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials.
-
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
4/23/2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA , Inc.
-
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
4/23/2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD).
-
Generic Drugs Market Size to Worth Around USD 779.68 Bn by 2033
4/23/2024
A recent market report published by nova one advisor, the global generic drugs market size was estimated at USD 465.19 billion in 2023 and is expected to be worth around USD 779.68 billion by 2033 with a CAGR of 5.3% from 2024 to 2033.
-
Third Generation Sequencing Market 2024-2031 | Increasing Demand for Real-Time Sequencing and Rapid Analysis
4/23/2024
Global Third Generation Sequencing Market in terms of revenue was estimated to be worth $10.07 Bn in 2023 and is poised to reach $27.66 Bn by 2031, growing at a CAGR of 13.73% from 2024 to 2031 according to a new report by InsightAce Analytic.
-
Epigenetics Market Size Forested to be Worth over USD 61.04 Bn by 2033
4/23/2024
According to the Vision Research Reports, the global epigenetics market size was estimated at around USD 14.65 billion in 2023 and it is forecasted to be worth over USD 61.04 billion by 2033 with a CAGR of 15.34% from 2024 to 2033
-
Direct-to-Consumer Genetic Testing Market Rising Rapidly at CAGR 24.43%
4/23/2024
The direct-to-consumer genetic testing market size is expected to be worth around USD 17.35 billion by 2033 and growing at a CAGR of 24.43% from 2024 to 2033, according to Vision Research Reports.
-
SpecialtyVETPATH Taps Proscia For A Full Transformation Of Its Pathology Operations
4/23/2024
SpecialtyVETPATH, a private, pathologist-owned, and pathologist-directed veterinary pathology laboratory, has selected Proscia®, a leading provider of digital and computational pathology solutions
-
Autoimmune Hepatitis Diagnosis and Treatment Market Size Set to Soar USD 19.15 Billion by 2032
4/23/2024
The global autoimmune hepatitis diagnosis and treatment market size is projected to increase from USD 14.03 billion in 2023 to approximately USD 19.15 billion by 2032. This growth, at a CAGR of 3.3% from 2023 to 2032
-
Cell-Based Assays Market Size is Projected USD 38.48 Billion by 2033
4/23/2024
The global cell-based assays market size is calculated at USD 18.25 billion in 2024 and it is increasing around USD 38.48 billion by 2033 with a CAGR of 8.64% from 2024 to 2033. U.S. cell-based assays market size was valued at USD 11.82 billion in 2023.
-
Lipid Nanoparticles (LNPs) CDMO Market to Reach USD 518.2 Million with a CAGR of 14.10% from 2024-2031
4/23/2024
Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.